Rebif and Panic attack - a phase IV clinical study of FDA data

Summary:

Panic attack is reported as a side effect among people who take Rebif (interferon beta-1a), especially for people who are female, 40-49 old, have been taking the drug for 2 - 5 years also take Clonazepam, and have Secondary progressive multiple sclerosis.

The phase IV clinical study analyzes which people have Panic attack when taking Rebif. It is created by eHealthMe based on reports of 60,837 people who have side effects when taking Rebif from the FDA, and is updated regularly.

What is Rebif?

Rebif has active ingredients of interferon beta-1a. It is often used in multiple sclerosis. eHealthMe is studying from 61,126 Rebif users. Check the latest studies of Rebif.

What is Panic attack?

Panic attack is found to be associated with 2,397 drugs and 2,081 conditions by eHealthMe. Check the latest studies of Panic attack.

On Apr, 12, 2026

60,837 people reported to have side effects when taking Rebif.
Among them, 202 people (0.33%) have Panic attack.

Among these 202 people:

How long have people been on Rebif when they have Panic attack? *

What is the gender of people who have Panic attack when taking Rebif? *

female: 85.43 %
male: 14.57 %

What is the age of people who have Panic attack when taking Rebif? *

What are other drugs people take besides Rebif? *

What are other side effects people have besides Panic attack? *

Stress And Anxiety: 67 people, 33.17%
Depression: 47 people, 23.27%
Weakness: 46 people, 22.77%
Fatigue (feeling of tiredness): 43 people, 21.29%
Hypoaesthesia (reduced sense of touch or sensation): 38 people, 18.81%
Dizziness: 37 people, 18.32%
Headache (pain in head): 35 people, 17.33%
Drowsiness: 34 people, 16.83%
Malaise (a feeling of general discomfort or uneasiness): 32 people, 15.84%
Memory Loss: 25 people, 12.38%

What are the existing conditions these people have? *

Secondary Progressive Multiple Sclerosis (a stage of ms which comes after relapsing remitting ms in many cases): 9 people, 4.46%
Depression: 7 people, 3.47%
Stress And Anxiety: 7 people, 3.47%
Gait Disturbance: 4 people, 1.98%
Asthma: 4 people, 1.98%
Primary Progressive Multiple Sclerosis (primary progressive inflammatory disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged): 4 people, 1.98%
High Blood Pressure: 3 people, 1.49%
Back Pain: 2 people, 0.99%
Pain: 2 people, 0.99%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 2 people, 0.99%

* Approximation only. Some reports may have incomplete information.

Do you take Rebif and have Panic attack?

- Check whether Panic attack is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Rebif:

Rebif (61,126 reports)

Panic attack treatments and more:

Panic attack (65,704 reports)

Browse all side effects of Rebif:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Panic attack:

Panic attack (2,397 drugs)

Browse all the conditions that are associated with Panic attack:

Panic attack (2,081 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on interferon beta-1a (the active ingredients of Rebif) and Rebif (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.